Bibliography
- Ferre F, Moss RB, Daigle A, Viral load in peripheral blood mononuclear cells as surrogate for clinical progression. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(Suppl 2):S51-56
- McKinney RE Jr. Antiretroviral therapy: evaluating the new era in HIV treatment. Adv Pediatr Infect Dis 1996;12:297-323
- Mayers DL. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Am J Med 1997;102(5B):70-5
- Landstrom AP, Tefferi A. Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia. Leuk Lymphoma 2006;47(3):397-402
- Hughes T, Deininger M, Hochhaus A, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108(1):28-37
- Cooper S, Giles FJ, Savona MR. Overcoming resistance in chronic myelogenous leukemia. Leuk Lymphoma 2009;50(11):1785-93
- Renneville A, Roumier C, Biggio V, Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008;22(5):915-31
- Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28(Suppl 1):S24-31
- LoRusso PM, Eder JP. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opin Invest Drugs 2008;17(7):1013-28
- Murdoch DA, Sager JBC. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol 2008;20(1):104-11
- Singer CF, Köstler WJ, Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim Biophys Acta Rev Cancer 2008;1786(2):105-13